Early therapy with neuraminidase inhibitors for influenza A (H1N1) pdm 2009 infection

被引:5
|
作者
Yamamoto, Takehisa [1 ]
Ihashi, Mai [1 ]
Mizoguchi, Yoshimi [1 ]
Kaneno, Hiroshi [1 ]
Yamamoto, Katsusuke [1 ]
Inoue, Yutaka [2 ]
Kase, Tetsuo [3 ]
Okabe, Nobuhiko [4 ]
Shimotsuji, Tsunesuke [1 ]
机构
[1] Minoh City Hosp, Dept Pediat, Minoh City, Osaka 5628562, Japan
[2] Minoh City Hosp, Dept Radiol, Minoh City, Osaka 5628562, Japan
[3] Osaka Prefectural Inst Publ Hlth, Osaka 537, Japan
[4] Kawasaki City Inst Publ Hlth, Kawasaki, Kanagawa 2100834, Japan
关键词
early therapy; estimated clinical severity; influenza A (H1N1) pdm 2009; mean covariance structure equation analysis; neuraminidase inhibitor; OSELTAMIVIR TREATMENT; CLINICAL-FEATURES; JAPAN ANALYSIS; A(H1N1); OUTCOMES; IMPACT; VIRUS;
D O I
10.1111/ped.12154
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
BackgroundNeuraminidase inhibitors have been reported to decrease mortality in patients infected with influenza A (H1N1) pdm 2009 (H1N1pdm09), but it is not clear whether they are effective againstH1N1pdm09 in apparently healthy children. MethodsThe effect of early treatment with neuraminidase inhibitors on 70 otherwise healthy children with possible H1N1pdm09 (pH1N1pdm09) infection was investigated. The children were simultaneously treated with a neuraminidase inhibitor (oseltamivir or zanamivir) and maoto, a Japanese traditional herbal medicine, which had been reported to be effective against seasonal influenza. Clinical severity was assessed using patient history, namely the worst values for clinical vital signs and laboratory data on admission. After refining these parameters with univariate, decision tree and multiple regression analysis, mean covariance structure equation analysis was used to investigate the association of estimated clinical severity to the selected parameters. ResultsTotal path analysis using a Bayesian method indicated that the estimated clinical severity of pH1N1pdm09 was positively associated with maximum body temperature, pulse rate, respiration rate, duration necessary for defervescence, admission duration and log urinary 2-microglobulin/creatinine level, and negatively associated with age and the presence and duration of treatment with the neuraminidase inhibitor in the outpatient clinic. ConclusionsThis study provides the first clinical evidence that early treatment with neuraminidase inhibitors in outpatient clinic decreased the estimated clinical severity of pH1N1pdm09 in apparently otherwise healthy pediatric inpatients.
引用
收藏
页码:714 / 721
页数:8
相关论文
共 50 条
  • [21] 2009 H1N1 Influenza
    Sullivan, Seth J.
    Jacobson, Robert M.
    Dowdle, Walter R.
    Poland, Gregory A.
    MAYO CLINIC PROCEEDINGS, 2010, 85 (01) : 64 - 76
  • [22] A(H1N1) pdm09 influenza infection: vaccine inefficiency
    Friedman, Nehemya
    Drori, Yaron
    Pando, Rakefet
    Glatman-Freedman, Aharona
    Sefty, Hanna
    Bassal, Ravit
    Stein, Yaniv
    Shohat, Tamy
    Mendelson, Ella
    Hindiyeh, Musa
    Mandelboim, Michal
    ONCOTARGET, 2017, 8 (20) : 32856 - 32863
  • [23] 2009 H1N1 Influenza
    Sullivan, Seth J.
    Jacobson, Robert M.
    Dowdle, Walter R.
    Poland, Gregory A.
    MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2010, 8 (01): : 68 - 80
  • [24] Incidence of Influenza A(H1N1) pdm09 Infection, United Kingdom, 2009-2011
    Sridhar, Saranya
    Begom, Shaima
    Bermingham, Alison
    Hoschler, Katja
    Adamson, Walt
    Carman, William
    Van Kerkhove, Maria D.
    Lalvani, Ajit
    EMERGING INFECTIOUS DISEASES, 2013, 19 (11) : 1866 - 1869
  • [25] Neurological complications of pandemic A(H1N1)2009pdm, postpandemic A(H1N1)v, and seasonal influenza A
    Radzisauskiene, Daiva
    Vitkauskaite, Monika
    Zvinyte, Karolina
    Mameniskiene, Ruta
    BRAIN AND BEHAVIOR, 2021, 11 (01):
  • [26] The novel influenza A/H1N1 or (2009) Influenza A/H1N1 or "Swine-origin influenza A (H1N1)"
    Cabezas Fernandez del Campo, Jose Antonio
    ANALES DE LA REAL ACADEMIA NACIONAL DE FARMACIA, 2009, 75 (04): : 947 - 963
  • [27] Pandemic (H1N1) 2009 and Seasonal Influenza A (H1N1) Co-infection, New Zealand, 2009
    Peacey, Matthew
    Hall, Richard J.
    Sonnberg, Stephanie
    Ducatez, Mariette
    Paine, Shevaun
    Nicol, Mackenzie
    Ralston, Jacqui C.
    Bandaranayake, Don
    Hope, Virginia
    Webby, Richard J.
    Huang, Sue
    EMERGING INFECTIOUS DISEASES, 2010, 16 (10) : 1618 - 1620
  • [28] Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: summary of an ecological study
    Miller, Paula E.
    Rambachan, Aksharananda
    Hubbard, Roderick J.
    Li, Jiabai
    Meyer, Alison E.
    Stephens, Peter
    Mounts, Anthony W.
    Rolfes, Melissa A.
    Penn, Charles R.
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2013, 7 : 82 - 86
  • [29] Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies
    Gao, Jin
    Couzens, Laura
    Burke, David F.
    Wan, Hongquan
    Wilson, Patrick
    Memoli, Matthew J.
    Xu, Xiyan
    Harvey, Ruth
    Wrammert, Jens
    Ahmed, Rafi
    Taubenberger, Jeffery K.
    Smith, Derek J.
    Fouchier, Ron A. M.
    Eichelberger, Maryna C.
    MBIO, 2019, 10 (02):
  • [30] A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus
    Abed, Y
    Goyette, N
    Boivin, G
    ANTIVIRAL THERAPY, 2004, 9 (04) : 577 - 581